We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.55% | 9.15 | 8.80 | 9.50 | 9.15 | 8.86 | 9.10 | 1,054,095 | 12:15:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.09 | 84.9M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/1/2022 07:43 | it also shows that omicron linage was probably a Beta Variant ... Fact is the omicron can reinfect .. same as the Beta variant so we are now at the forefront .... because we have the right product at the right time with the potential to broaden to universal .. a buying opportunity and another window for a Panama Rant ... ffs | inanaco | |
31/1/2022 07:34 | sorted ....... They clearly see the data coming from the trial is worthy ! The UCT Lung Institute remains highly motivated to investigate the clinical potential of the SCOV1 and SCOV2 vaccines with our colleagues at Scancell." | inanaco | |
31/1/2022 07:30 | Great there are no safety issues so far. | chillpill | |
31/1/2022 07:19 | Good news today, confirming Covidity is effective against Omicron, especially SCOV-2. More data needed asap though - it would be good to get a partner in and accelerate! | emptyend | |
31/1/2022 07:16 | Mon, 31st Jan 2022 07:00 RNS Number : 0599A Scancell Holdings Plc 31 January 2022 31 January 2022 Scancell Holdings plc ("Scancell" or the "Company") Update on COVIDITY Phase 1 clinical trial in South Africa First patient dosed with second COVIDITY vaccine candidate (SCOV2) Preclinical studies demonstrate strong immunity against Omicron Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces further progress of the Phase 1 COVIDITY clinical trial being conducted at the University of Cape Town (UCT) Lung Institute in South Africa. The objectives of the first part of the trial are to assess the safety and immunogenicity of two vaccine candidates, SCOV1 and SCOV2, in healthy, vaccine-naïve subjects, prior to testing as a booster in volunteers who have already received an approved vaccine. To date, 16 subjects have been enrolled and the SCOV1 immunisations have been well tolerated, with no safety concerns. As per protocol, we can now report that the first subject has received their first injection with the second vaccine candidate SCOV2, following two injections with SCOV1. As announced at the Company's interim results, due to the high case numbers of the Omicron variant in South Africa, recruitment has been slow to date but, now the country's wave of infections has passed, screening is continuing at an increased rate, with further safety and immunogenicity data still expected to be available in H1 2022. Scancell has previously shown in preclinical models that both SCOV1 and SCOV2 induce high titre antibodies and potent T cells against both the S and N antigens, and that these responses cross-reacted with the Delta variant. The Company has now confirmed in preclinical studies that although both vaccines induced responses against the Omicron variant, the strongest responses were seen with SCOV2. Honorary Prof Rod Dawson, Managing Director of the University of Cape Town Lung Institute, commented: "There is still a need for additional SARS-CoV-2 vaccines that are safe and effective to achieve long-lasting protection against new and emerging variants. The UCT Lung Institute remains highly motivated to investigate the clinical potential of the SCOV1 and SCOV2 vaccines with our colleagues at Scancell." Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "We are delighted that the first subject has now received a SCOV2 injection in the COVIDITY Phase 1 clinical trial. The Scancell team and collaborators remain convinced that a more durable and broader-acting vaccine is required to combat the global pandemic and we are encouraged by the emerging data supporting the use of our vaccines against new variants." | goyathlay | |
30/1/2022 17:59 | Gazza, so several of you have had similar symptoms and all tested negative, so it is something else that has caused the symptoms that is why I am suggesting some sort of radiation, sounds far fetched but worth asking the question of your Dcotor. | panama7 | |
30/1/2022 17:54 | Panama, I have tested (ltfr and per) and they have consistently come out negative. Work colleagues have had identical symptoms and tested negative. I have had no physical contact with these as I have worked from home since March 3rd 2020. | gazza | |
30/1/2022 17:41 | Gazza, I had very mild cold like symptoms a few weeks ago and put it down to Omicron. A week later I had other symptoms the main one being a chest infection that has taken ages to get rid of. I wouldn't describe these new symptoms as cold or flu like. Someone I was with has had very similar symptoms but has also suffered from dizzy spells. These are not normal symptoms I would expect with flu or a cold. There has been a lot of talk about radiation sickness ( one of the first Doctor's in NYC posted on social media that the symptoms he was seeing were like altitude or radiation sickness ) This sounds like conspiracy theory stuff but over the last two years this has been mentioned too many times for it just to be coincidence. I have not been to the Doctor or been tested , Gazza maybe it might be worth asking the question if you are going to the Doctors. | panama7 | |
30/1/2022 17:27 | Corruption in the EU, if you think it is any different in the UK think again........hxxps:/ | panama7 | |
30/1/2022 17:10 | Hi TF, "Are you quite well today ?"Actually no. I have had the worst cold ever (past 6 weeks) that has turned into a chest infection. I haven't been this I'll since 2008. I hadn't had asthma medication for 10 years but now back on it. Finished a course of antibiotics but no better. I will be at the docs tomorrow to get more I suspect. Maybe there is something in what Panama has been saying after all? | gazza | |
30/1/2022 15:58 | Gazza, 08:20 your best post for ages. It has never ever been about the Science it has always been about an agenda. You don't destroy Economies, Health systems, jobs, livelihoods, education, travel without an agenda. Mark Carney speaking on behalf of the WEF a couple of years ago stated " Businesses that don't adjust will not be viable " what he meant was " we are going to put so many restrictions in place on small independent businesses that they won't survive " that is exactly what is happening. Millions of SME's destroyed across the World, 10's of millions of jobs destroyed, 100's of millions forced into poverty. The likes of you, Inane, Bermuda, EE, ww, TF have all supported the measures and all of you have supported Crimes Against Humanity with your compliance and your pushing of the Vaccines. | panama7 | |
30/1/2022 15:58 | Gazza, 08:20 your best post for ages. It has never ever been about the Science it has always been about an agenda. You don't destroy Economies, Health systems, jobs, livelihoods, education, travel without an agenda. Mark Carney speaking on behalf of the WEF a couple of years ago stated " Businesses that don't adjust will not be viable " what he meant was " we are going to put so many restrictions in place on small independent businesses that they won't survive " that is exactly what is happening. Millions of SME's destroyed across the World, 10's of millions of jobs destroyed, 100's of millions forced into poverty. The likes of you, Inane, Bermuda, EE, ww, TF have all supported the measures and all of you have supported Crimes Against Humanity with your compliance and your pushing of the Vaccines. | panama7 | |
30/1/2022 15:47 | Inane, " deletegate " yeah highlights the corruption between Big Pharma and the European Commission but don't think for one minute the same has not gone on in the UK. Pfizer also gave 2bn USD to the Vatican to promote the Vaccines. Don't for one minute think that the contracts signed with the EU are any different from the UK. Part of those contracts 1) not being allowed to travel without vaccine 2) kids not going to School without vaccine, hence why the Government overruled the JCVI in authorising the vaccine for kids. | panama7 | |
30/1/2022 11:50 | I wonder when the first patient will be dosed? We have previously described our Modi-1 peptide vaccine (60), this vaccine comprises of two citrullinated vimentin peptides, as well as a citrullinated peptide from α-enolase, each peptide is conjugated to the TLR1/2 ligand adjuvant AMPLIVANT® (ISA Pharmaceuticals BV, Leiden, the Netherlands). In preclinical studies we have shown that by combining a peptide vaccine with a TLR ligand adjuvant promotes a Th1 response that is capable of inducing a potent anti-tumor response in tumor bearing mice (60). The CD4+ but not CD8+ T cells were essential for the generation of the anti-tumor response, depleting CD4+ T cells abrogated this response and a corresponding increase in CD4+ tumor-infiltrating lymphocytes (TILs) was associated with tumor regression (60). A comparison of different Toll-like receptor (TLR)-stimulating adjuvants showed that Modi-1 induced strong Th1 responses when combined with GM-CSF, TLR9/TLR4, TLR9, TLR3, TLR1/2 and TLR7 agonists. The strongest response was observed with TLR1/2 AMPLIVANT® adjuvant. The AMPLIVANT® adjuvant is already being used in an ongoing study evaluating two HPV-16 peptides in patients with head and neck squamous cell carcinoma (NCT02821494). These results highlight the importance of screening a range of adjuvants and doses to find the optimal adjuvant and dose to induce a potent immune response. The Modi-1 vaccine will enter a Phase 1/2 clinical trial in 2021. | marcusl2 | |
30/1/2022 10:47 | Inan - I wondered if you made any progress with Dr JC ? Thanks for trying anyway. | torquayfan | |
30/1/2022 09:39 | Gazza - Of course it's not all about the science, (even though claims were made persistently that it was). I'm just noting our daily doses have disappeared. I thought I was being rather supportive of Boris this time. Are you quite well today ? BFN | torquayfan | |
30/1/2022 08:44 | The EU's corrupt and renegade Executive with Broomsticks' filthy little texting fingerprints all over the latest scandal. Incompetent European politicians are always guaranteed a nice little gig in Brussels. As the saying goes, with the EU, 'you fail upwards'. | goyathlay | |
30/1/2022 08:35 | Delete-gate is bigger than the texts The European Parliament must insist on holding the European Commission accountable. How to buy a vaccine Burner Phones | inanaco | |
30/1/2022 08:25 | Panama, "They were given a crime number by the Met, 6029679/21, to show that the police are taking it seriously"Surely the police are obliged to take ALL reports of crime seriously? | gazza | |
30/1/2022 08:20 | TF, I keep telling you, it's NOT all about the science. You cannot just focus on one disease. How would you feel if the government told everyone to stay indoors from December to February to avoid getting frost bite? I know Covid is a far bigger risk than frostbite but I use an extreme case to illustrate a point - whilst following "the science" on a single issue, "the science" has been totally cast aside on others. For example, "the science" on cancer care is clear - early diagnosis saves lives. Prof Karol Sikora reckons at least 50,000 extra cancer deaths during the pandemic. The average age of people dying from Covid is 82.5. (Taken from ONS site). The average age of men getting testicular cancer is 32. Now, if an 82 year old and a 30 year old were admitted to A&E following a car crash, who would get priority attention?As well as medical factors there are social, mental and economic issues as well. I guess you ignore these as they don't fit your Boris bashing agenda. | gazza |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions